Recruiting
Royal Jelly as a Strategy to Modulate Inflammation and Oxidative Stress in Patients With Systemic Arterial Hypertension
The study aims to evaluate the effect of the royal jelly on inflammation and oxidative stress in participants with systemic arterial hypertension. A longitudinal double-blind randomized clinical trial will be carried out, involving hypertensive participants for two months.
ClinicalTrials.gov IDNCT06917131
PhaseNA
Enrollment34
SponsorUniversidade Federal Fluminense
Age18 Years
SexALL
Conditions studied
Hypertension, Cardiovascular Diseases (CVD), Inflammation
About this study
The study aims to evaluate the effect of the royal jelly on inflammation and oxidative stress in participants with systemic arterial hypertension. A longitudinal double-blind randomized clinical trial will be carried out, involving hypertensive participants for two months.
Interventions
- Dietary Supplement: Royal Jelly — Participants will receive 2 capsules per day, providing the dosage of 300mg of royal jelly for 2 months (8 weeks).
- Dietary Supplement: Placebo — The placebo group will receive 2 capsules per day (containing microcrystalline cellulose and magnesium stearate in colored gelatin capsules capable of masking the appearance of the internal content), at the same time for 2 months.
Primary outcomes
- Change of inflammatory transcripton factor (Baseline and 8 weeks)
Eligibility information
Inclusion Criteria:
* Diagnosis of stage 1 hypertension
* Regular treatment for more than 6 months
* No changes in medication doses during the last 3 months
Exclusion Criteria:
* Autoimmune diseases
* Infectious diseases
* Diabetes
* Chronic kidney disease
* Liver disease
* Cancer
* AIDS
* Pregnant women
* Use of catabolic drugs or antibiotics
* Use of antioxidant vitamin supplements, prebiotics, probiotics, or synbiotics
* Habitual intake of royal jelly
* Allergy to bee stings
* Acute myocardial infarction (AMI)
* Stroke (CVA)
Study locations
- Denise Mafra, Rio de Janeiro, Rio de Janeiro 22260050 Brazil
Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.
Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-27.